
Barbara WiÅ>niowska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4665236/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Collation, assessment and analysis of literature <i>in vitro</i> data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. Journal of Applied Toxicology, 2009, 29, 183-206.	2.8	103
2	Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacology & Toxicology, 2016, 17, 12.	2.4	54
3	Virtual population generator for human cardiomyocytes parameters:in silicodrug cardiotoxicity assessment. Toxicology Mechanisms and Methods, 2012, 22, 31-40.	2.7	27
4	Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram. AAPS Journal, 2018, 20, 6.	4.4	23
5	hERG in vitro interchange factors—development and verification. Toxicology Mechanisms and Methods, 2009, 19, 278-284.	2.7	22
6	BDTcomparator: a program for comparing binary classifiers. Bioinformatics, 2011, 27, 3439-3440.	4.1	22
7	In vitro–in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discovery Today, 2014, 19, 275-281.	6.4	22
8	Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. AAPS Journal, 2015, 17, 1025-1032.	4.4	22
9	Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations. Current Pharmacology Reports, 2016, 2, 171-177.	3.0	20
10	Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity. Drug Discovery Today, 2017, 22, 10-16.	6.4	19
11	From Heuristic to Mathematical Modeling of Drugs Dissolution Profiles: Application of Artificial Neural Networks and Genetic Programming. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-9.	1.3	17
12	Better prediction of the local concentration–effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development. Drug Discovery Today, 2019, 24, 1344-1354.	6.4	17
13	Prediction of the hERG potassium channel inhibition potential with use of artificial neural networks. Applied Soft Computing Journal, 2011, 11, 2611-2617.	7.2	15
14	Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example. Journal of Pharmaceutical Sciences, 2016, 105, 3415-3424.	3.3	15
15	Computer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challenges. Europace, 2014, 16, 724-735.	1.7	14
16	The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation. Current Pharmacology Reports, 2016, 2, 339-344.	3.0	13
17	Tox-Database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition. BMC Pharmacology & amp; Toxicology, 2012, 13, 6.	2.4	12
18	Predictive model for Lâ€ŧype channel inhibition: multichannel block in QT prolongation risk assessment. Journal of Applied Toxicology, 2012, 32, 858-866.	2.8	12

#	Article	IF	CITATIONS
19	Enhanced QSAR models for drugâ€ŧriggered inhibition of the main cardiac ion currents. Journal of Applied Toxicology, 2015, 35, 1030-1039.	2.8	12
20	Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. AAPS Journal, 2018, 20, 47.	4.4	10
21	Virtual Thorough QT (TQT) Trial—Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine. AAPS Journal, 2018, 20, 83.	4.4	10
22	Evaluation of patients' adherence to statins in Poland. Current Medical Research and Opinion, 2011, 27, 99-105.	1.9	9
23	Slow delayed rectifying potassium current (<i>I</i> _{Ks}) – analysis of the <i>in vitro</i> inhibition data and predictive model development. Journal of Applied Toxicology, 2013, 33, 723-739.	2.8	9
24	The open-access dataset for insilico cardiotoxicity prediction system. Bioinformation, 2011, 6, 244-245.	0.5	8
25	Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models. Journal of Applied Toxicology, 2018, 38, 450-458.	2.8	7
26	Magnetic Core–Shell Molecularly Imprinted Nano-Conjugates for Extraction of Antazoline and Hydroxyantazoline from Human Plasma—Material Characterization, Theoretical Analysis and Pharmacokinetics. International Journal of Molecular Sciences, 2021, 22, 3665.	4.1	5
27	Thorough QT (TQT) studies: concordance with torsadogenesis and an evolving cardiac safety testing paradigm. Drug Discovery Today, 2017, 22, 1460-1465.	6.4	4
28	Humans Vary, So Cardiac Models Should Account for That Too!. Frontiers in Physiology, 2017, 8, 700.	2.8	4
29	An Open-Access Dataset of Thorough QT Studies Results. Data, 2020, 5, 10.	2.3	4
30	Open-access database of literature derived drug-related Torsade de Pointes cases. BMC Pharmacology & Toxicology, 2022, 23, 7.	2.4	3
31	Quantitative Assessment of the Physiological Parameters Influencing QT Interval Response to Medication: Application of Computational Intelligence Tools. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-11.	1.3	2
32	Characterization of In Vitro and In Vivo Metabolism of Antazoline Using Liquid Chromatography-Tandem Mass Spectrometry. International Journal of Molecular Sciences, 2020, 21, 9693.	4.1	2
33	How circadian variability of the heart rate and plasma electrolytes concentration influence the cardiac electrophysiology – model-based case study. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 387-399.	1.8	1
34	Prediction of the hERG Potassium Channel Inhibition Potential with Use of the Artificial Neural Networks. Advances in Intelligent and Soft Computing, 2010, , 91-99.	0.2	1
35	How in vitro influences in silico utilized for the prediction of in vivo - pilot study of the drug-induced pro-arrhythmic potency prediction. Folia Medica Cracoviensia, 2015, 55, 5-19.	0.3	1
36	Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating. Pharmaceuticals, 2022, 15, 379.	3.8	1

Barbara WiÅ>niowska

#	Article	IF	CITATIONS
37	Drug–physiology interaction and its influence on the QT prolongation-mechanistic modeling study. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 483-490.	1.8	0
38	Effect of multiple drugs interacting with the hERG channel—In vitro study. Journal of Pharmacological and Toxicological Methods, 2018, 93, 118.	0.7	0
39	Evolutionary Algorithms in Modeling Aerodynamic Properties of Spray-Dried Microparticulate Systems. Applied Sciences (Switzerland), 2020, 10, 7109.	2.5	0
40	Development of physiologically based pharmacokinetic model for the immediate release ropinirole tablets. Acta Poloniae Pharmaceutica, 2021, 78, 317-328.	0.1	0